Prescribing information

 

_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Welcome to the TAFINLAR® + MEKINIST® on-demand webinars page.

Below you can access recordings of the latest educational webinars organised by Novartis and hosted by experts in the field of lung cancer. We’ll continue to add to the collection, so keep checking back!

 

Targeted therapy for BRAF+ NSCLC patients

Dr Tom Newsom-Davis, Dr Alastair Greystoke, Dr Riyaz Shah and Dr Toby Talbot come together to discuss the current testing landscape, the clinical data for Dabfrafenib+Trametinib in NSCLC and what can be learnt from the clinical experience in the melanoma setting.

Register to watch the full video
or specific topic highlights

 

Indication: Tafinlar in combination with Mekinist is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

References

  1. Tafinlar (dabrafenib) Summary of Product Characteristics.
  2. Mekinist (trametinib) Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | April 2021 | 118583
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]